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Segmental neuroﬁbromatosis type 1 (NF1) is an under-recognized form of NF1 caused by
postzygotic somatic loss-of-function NF1 gene mutations that aﬀect a subset of cells in the body.1
This is in contrast to classic or generalized NF1, in which a germline NF1 gene mutation aﬀects all
diploid cells in the body. In the segmental NF1 variant, individuals typically exhibit clinical
features characteristic of generalized NF1, such as café-au-lait macules (CALMs), skinfold
freckling, and neuroﬁbromas, restricted to one segment of the body. For this reason, establishing
the diagnosis can be challenging because the underlying NF1 gene mutation is often not detected
in the blood. Underscoring the challenges of caring for individuals with this variant of NF1, we
describe a woman with segmental NF1 referred to us at 22 years of age for evaluation.
The patient ﬁrst came to medical attention at four months of age when her pediatrician noted that
she had more than six CALMs localized to her right abdomen, back, and hip. Over the next ﬁve
years, she developed additional hyperpigmented macules in this region, followed by freckling in
the right inguinal region. Collectively, these ﬁndings met the criteria for a diagnosis of segmental
NF1. On examination, the CALMs and skinfold freckling in the aﬀected region did not cross
either the anterior or posterior midlines, and there were no neuroﬁbromas, other hyperpigmented
lesions, or Lisch nodules detected. Because the aﬀected body segment could potentially include
her right ovary, at 28 years of age, she underwent genetic testing (direct Sanger sequencing, mixed
ligation-dependent probe ampliﬁcation, and interphase ﬂuorescence in situ hybridization
[FISH]), which failed to identify an NF1 gene mutation in her blood. She subsequently underwent biopsy of three of her CALMs (right lower back, hip, and abdomen), followed by primary
culture of these skin melanocytes for genetic testing as above.2 As shown in the ﬁgure, sequencing
and FISH revealed that all three CALM-derived melanocyte cultures shared a common 1.4
megabase deletion of the NF1 gene (type 1 total gene deletion [TGD]). Furthermore, in each
of the three CALMs, a diﬀerent second-hit mutation was identiﬁed that aﬀected the remaining
(non-deleted) NF1 gene copy.
This case report is instructive for several reasons. First, it underscores the utility of analyzing the
aﬀected tissues (e.g., melanocytes from multiple CALMs), rather than the blood, in establishing
a diagnosis of segmental NF1. Although this patient met the diagnostic criteria for segmental
NF1 on clinical grounds (regional distribution of CALMs and inguinal freckling), the genetic
ﬁndings provide a reference for future prenatal genetic counseling and diagnostic testing.3
Second, genetic testing of aﬀected tissue suggests that this patient sustained a total NF1 gene
deletion during post-zygotic development and thus aﬀected only a subset of her cells. Individuals with the generalized form of NF1 who harbor this type of mutation (type 1 TGD)
frequently have a more severe phenotype, with greater numbers of neuroﬁbromas and an
increased risk of cancer, compared with individuals with generalized NF1 caused by other NF1
gene mutations.4 By contrast, this patient with segmental NF1 has no visible neuroﬁbromas and
is otherwise healthy, which is diﬀerent from a previous report of several patients with segmental
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Figure Unique second neurofibromatosis type 1 (NF1) gene mutations in multiple café-au-lait macules (CALMs) from an
individual with segmental NF1

(A) Segmental or mosaic NF1 is caused by de novo NF1 gene mutations that occur during postzygotic development and affect only a subset of cells in the body.
Genetic testing of melanocytes derived from three different CALMs in the patient’s affected body segment (denoted by the diagonal stripes) revealed
a common 1.4 megabase (MB) deletion, resulting in total loss of one copy of the NF1 gene, and three unique second-hit mutations affecting the remaining NF1
allele. The insets depict both NF1 gene copies in the indicated cell types. (B) Locations (colored pinheads) and predicted messenger RNA (mRNA) and protein
changes resulting from the second NF1 gene mutations in melanocytes derived from three different CALMs. Two intronic mutations were located within splice
sites, and one exonic mutation resulted in a premature stop codon (nonsense mutation). Short black boxes denote introns; tall gray boxes denote exons.

NF1 and type 1 TGDs.5 In that series, four of the ﬁve cases
had either numerous dermal neuroﬁbromas or a plexiform
neuroﬁbroma. The less severe phenotype in the current
subject suggests that, compared with previously reported
cases, (1) her total NF1 gene deletion may have arisen at
a later developmental stage, (2) it is restricted to a diﬀerent
population of cells, or (3) modiﬁer genes additionally inﬂuence clinical expression. Third, each of the CALMs in this
patient contained melanocytes harboring a unique second
NF1 gene mutation that presumably resulted in loss of or
impaired function of the NF1-encoded protein (neuroﬁbromin) in those cells. This ﬁnding is consistent with
previous reports demonstrating biallelic NF1 gene inactivation in CALMs,6,7 similar to that observed in benign
tumors from patients with NF1.2 The ﬁnding that the
second-hit mutations were distinct in each CALM argues
that each macule arose independently, similar to benign
2

Neurology: Genetics | Volume 4, Number 4 | August 2018

neoplasms (i.e., neuroﬁbromas) that arise in this population
of tumor-prone individuals.
Author contributions
M.E. Freret contributed to manuscript preparation and made
the ﬁgure. C. Anastasaki contributed to manuscript preparation. D.H. Gutmann wrote the ﬁrst draft of the manuscript.
Study funding
This work was supported by the NIH (1-R35-NS07211-01,
D.H. Gutmann).
Disclosure
M.E. Freret and C. Anastasaki report no disclosures. D.H.
Gutmann holds patents for the identiﬁcation of the ND1 gene
and mTOR regulator; has received research support from the
US Army Department of Defense, the Giorgio Foundation,
Neurology.org/NG

the Children’s Tumor Foundation, and the Neuroﬁbromatosis Acceleration Therapeutics Program; receives license fee
payments for the TSC1 knockout mouse; and receives royalty
payments for the NF1 gene patent. Full disclosure form information provided by the authors is available with the full
text of this article at Neurology.org/NG.

2.

3.
4.
5.

Received March 20, 2018. Accepted in ﬁnal form April 24, 2018.

6.

References

7.

1.

Listernick R, Mancini AJ, Charrow J. Segmental neuroﬁbromatosis in childhood. Am J
Med Genet A 2003;121A:132–135.

Neurology.org/NG

Maertens O, De Schepper S, Vandesompele J, et al. Molecular dissection of isolated
disease features in mosaic neuroﬁbromatosis type 1. Am J Hum Genet 2007;81:
243–251.
Ko Y, Lee C, Lee H, Lee M, Lee JS. Clinical application of next-generation sequencing
for the diagnosis of segmental neuroﬁbromatosis. J Dermatol Sci 2017;88:370–372.
Kehrer-Sawatzki H, Mautner VF, Cooper DN. Emerging genotype-phenotype relationships in patients with large NF1 deletions. Hum Genet 2017;136:349–376.
Messiaen L, Vogt J, Bengesser K, et al. Mosaic type-1 NF1 microdeletions as a cause of
both generalized and segmental neuroﬁbromatosis type-1 (NF1). Hum Mutat 2011;
32:213–219.
Eisenbarth I, Assum G, Kaufmann D, Krone W. Evidence for the presence of the
second allele of the neuroﬁbromatosis type 1 gene in melanocytes derived from cafe
au laitmacules of NF1 patients. Biochem Biophys Res Commun 1997;237:138–141.
De Schepper S, Maertens O, Callens T, Naeyaert JM, Lambert J, Messiaen L. Somatic
mutation analysis in NF1 cafe au lait spots reveals two NF1 hits in the melanocytes.
J Invest Dermatol 2008;128:1050–1053.

Neurology: Genetics | Volume 4, Number 4 | August 2018

3

Independent NF1 mutations underlie café-au-lait macule development in a woman with
segmental NF1
Morgan E. Freret, Corina Anastasaki and David H. Gutmann
Neurol Genet 2018;4;
DOI 10.1212/NXG.0000000000000261
This information is current as of July 23, 2018
Updated Information &
Services

including high resolution figures, can be found at:
http://ng.neurology.org/content/4/4/e261.full.html

References

This article cites 7 articles, 0 of which you can access for free at:
http://ng.neurology.org/content/4/4/e261.full.html##ref-list-1

Subspecialty Collections

This article, along with others on similar topics, appears in the
following collection(s):
All Clinical Neurology
http://ng.neurology.org//cgi/collection/all_clinical_neurology
All Genetics
http://ng.neurology.org//cgi/collection/all_genetics
Neurofibromatosis
http://ng.neurology.org//cgi/collection/neurofibromatosis

Permissions & Licensing

Information about reproducing this article in parts (figures,tables) or in
its entirety can be found online at:
http://ng.neurology.org/misc/about.xhtml#permissions

Reprints

Information about ordering reprints can be found online:
http://ng.neurology.org/misc/addir.xhtml#reprintsus

Neurol Genet is an official journal of the American Academy of Neurology. Published since April 2015, it is
an open-access, online-only, continuous publication journal. Copyright Copyright © 2018 The Author(s).
Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.. All rights
reserved. Online ISSN: 2376-7839.

